Traders bought shares of Abbott Laboratories (NYSE:ABT) on weakness during trading on Thursday after an insider sold shares in the company. $82.71 million flowed into the stock on the tick-up and $47.96 million flowed out of the stock on the tick-down, for a money net flow of $34.75 million into the stock. Of all stocks tracked, Abbott Laboratories had the 26th highest net in-flow for the day. Abbott Laboratories traded down ($0.33) for the day and closed at $54.73Specifically, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the firm’s stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $56.21, for a total value of $5,430,054.63. Following the completion of the sale, the executive vice president now owns 142,082 shares in the company, valued at approximately $7,986,429.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Miles D. White sold 276,886 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total transaction of $15,065,367.26. Following the completion of the sale, the chairman now owns 3,677,913 shares of the company’s stock, valued at approximately $200,115,246.33. The disclosure for this sale can be found here. Insiders sold a total of 616,332 shares of company stock valued at $33,579,226 in the last 90 days. Corporate insiders own 0.76% of the company’s stock.
Several equities research analysts have weighed in on the stock. BMO Capital Markets upgraded shares of Abbott Laboratories from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $58.00 to $65.00 in a research report on Tuesday. Barclays raised their price objective on shares of Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, September 28th. Zacks Investment Research cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Stifel Nicolaus raised their price objective on shares of Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, October 19th. Finally, Cowen reiterated a “buy” rating on shares of Abbott Laboratories in a research report on Sunday, September 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $57.56.
The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. The stock has a market cap of $95,260.00, a PE ratio of 23.11, a P/E/G ratio of 2.09 and a beta of 1.55.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Investors of record on Friday, October 13th were issued a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a yield of 1.93%. The ex-dividend date was Thursday, October 12th. Abbott Laboratories’s dividend payout ratio is currently 87.60%.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Tributary Capital Management LLC acquired a new position in Abbott Laboratories during the third quarter valued at approximately $106,000. Heritage Trust Co grew its holdings in Abbott Laboratories by 10.1% during the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after purchasing an additional 200 shares during the period. Winfield Associates Inc. grew its holdings in Abbott Laboratories by 3.9% during the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after purchasing an additional 89 shares during the period. Thompson Davis & CO. Inc. grew its holdings in Abbott Laboratories by 17.7% during the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after purchasing an additional 370 shares during the period. Finally, JFS Wealth Advisors LLC grew its holdings in Abbott Laboratories by 349.0% during the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after purchasing an additional 2,094 shares during the period. Hedge funds and other institutional investors own 71.32% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Investors Buy Shares of Abbott Laboratories (ABT) on Weakness After Insider Selling” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/14/investors-buy-shares-of-abbott-laboratories-abt-on-weakness-after-insider-selling.html.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
What are top analysts saying about Abbott Laboratories? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abbott Laboratories and related companies.